Opening the book…
In June 2024, a warning about a routine laboratory supply raised an important question: How would laboratories keep testing if deliveries slowed? BD Life Sciences had notified users on June 11 that some BD BACTEC blood culture media bottles could face intermittent supply delays. On July 10, CDC shared the warning with clinical laboratory professionals and directed them to FDA recommendations for prioritizing and conserving the bottles.
The concern centered on a small item with an important purpose. Blood culture testing helps clinical teams investigate bloodstream infections. The bottle is part of the path from a patient’s blood sample to information used in care. Without a dependable supply,
laboratories could need to reconsider how they organized their work. The situation shows how a supplier problem can reach far beyond a purchasing office.
On July 10, BD explained that its supplier was providing fewer vials than needed. In its public statement, the company described several efforts to reduce delays: helping the supplier with manufacturing expertise, using air shipments, and changing manufacturing schedules to speed production. It also reported that a former supplier of glass vials would restart production to help cover the gap. These were measures reported by BD; the statement did not independently establish how well each measure worked.
By March 14, 2025, the public guidance had changed. FDA announced that the blood culture media bottle shortage had resolved and that its conservation recommendations were no longer needed. That announcement described the national status reported on that date; it did not establish that every laboratory had the same inventory or delivery experience.
The notices document a supply disruption and a later announcement that it had resolved. They also raise planning questions for laboratories: How should purchasing, laboratory staff, clinical leaders, and quality personnel coordinate during a shortage? The following discussion applies the chapter concepts to that question; it does not describe one laboratory’s documented actions.
A laboratory facing such a disruption would need reliable answers to practical questions. How many usable bottles are available? Which deliveries are confirmed? Who reviews that information? Who may approve a temporary change, and what evidence is required? An inventory count is useful only when people know how to act on it.
Purchasing could gather delivery updates while laboratory operations checked inventory and expected use. Designated clinical and laboratory leaders would make decisions within their authority, with quality personnel supporting controlled instructions and records. These are proposed responsibilities, not documented assignments at a specific laboratory.
A quality plan would give those connections a clear structure. It could name the person responsible for reviewing supplies, identify the conditions that trigger escalation, and explain how staff receive approved updates. Any proposed substitute would need assessment before use. Availability alone would not show that an alternative was suitable for the laboratory’s equipment and methods.
A simple estimate can support this proposed planning. If a laboratory had 600 usable bottles and used 100 per day, with no new deliveries, 600 ÷ 100 would suggest about six days of supply. This is a hypothetical estimate, not a clinical recommendation or a guarantee of coverage. Bottle types, expiration dates, demand, and deliveries could change the estimate and the needed response.
The aim would be appropriate testing and patient care. A target to conserve supplies must remain tied to that purpose and to authorized clinical and laboratory decisions. Counting fewer bottles alone would not establish that the plan was successful.
When supply improved, a laboratory using temporary arrangements would need to check its own conditions before ending them. Authorized staff could confirm supplies, approve the return to routine instructions, and communicate an effective date. Superseded temporary instructions would be removed from routine use while preserving their history.
A quality plan needs to support both disruption and recovery. It connects reliable information with named responsibilities, decision authority, and follow-up. The public notices establish what CDC, BD, and FDA reported. A local laboratory would need its own records to evaluate whether its response worked.
This page titled 4.9: Example - When a bottle shortage challenged laboratory planning was last modified on Mon, 02 Nov 2026 07:02:27 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.
The book could not be loaded just now.